Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value
Amgen earnings beat estimates, and MariTide's promising Phase 2 results suggest significant differentiation from competitors.
Amgen Stock Adds Good Weight After CEO’s Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.
Kodiak Sciences Data At ARVO 2024 Highlight Depth Of Early And Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built On Kodiak’s Antibody Biopolymer Conjugate Platform
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple
OrthoPediatrics Corp. Receives “Breakthrough Device” Designation From FDA For eLLi Growing Rod System For Pediatric Patients With Scoliosis
OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the "Breakthrough Device" Designation from the Food
enGene To Present Details Of Its Pivotal Phase 1/2 LEGEND Study Of EG-70 In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ At The American Urology Association 2024 Annual Meeting
Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerationsBOSTON and MONTREAL, May 2, 2024 /CNW/
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution For Oncology And Inherited Disease Applications
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for
ImmunityBio, Serum Institute Of India Agree On An Exclusive Arrangement For Global Supply Of Bacillus Calmette-Guerin Across All Cancer Types
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio's recently approved treatment for non-muscle invasive bladder cancer (NMIBC)Serum Institute of India
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand.
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.